Professor Henry Woo

MBBS (Syd), DMedSc(Syd), FRACS(Urol), FACS
Professor of Urology, ANU College of Health and Medicine
Director of Uro-Oncology, Professor of Robotic Cancer Surgery, Chris O'Brien Lifehouse
Head, Department Urology and Director of SAN Prostate Centre of Excellence, Sydney Adventist Hospital

Henry Woo is a Urological Surgeon sub-specialising in Prostate Surgery. He is Professor of Urology at the College of Health and Medicine of the Australian National University. He is the Head of the Department of Urology and the Director of the SAN Prostate Centre of Excellence at the Sydney Adventist Hospital. He also serves as the Deputy Chair of the Medical Advisory Council at the Sydney Adventist Hospital. He is also Director of Uro-Oncology and Professor of Robotic Cancer Surgery at the Chris O'Brien Lifehouse.

Henry has extensive clinical trials experience in the areas of prostate cancer and benign prostate disease in various capacities ranging from site principal investigator through to trial management committee membership of large funded studies.

He is on the Board of Directors of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group as well as the charitable Australasian Urological Foundation. He runs a busy clinical trials unit, Australian Clinical Trials (ACT) Pty Ltd and provides opportunity for his patients to access novel treatments under clinical trial evaluation. He has been active member of the Urological Society of Australia New Zealand (USANZ) where he has held a number of senior positions over the years including Chair of the NSW Section, Convenor of the Annual Scientific Meeting and Chair of Continuing Professional Development to name a few.

He is a Fellowship Elected Councillor of the Royal Australasian College of Surgeons and currently serves as the Chair of the Research and Academic Surgery Committee, He has previously served as the Chair of the Australian and New Zealand Scholarships and Grants Committee.


Specialisation

  • Surgery
  • Urology

Research interests

Benign prostatic hyperplasia

Prostate cancer